Cefamandole Nafate for Injection Page 1 of 7
Cefamandole Nafate for
Injection
Eli Lilly and Company Effective Date: 25-Feb-2006
Material Safety Data Sheet
Section 1 - Chemical Product and Company
Manufacturer's Emergency Phone:
Manufacturer:
1-317-276-2000
Eli Lilly and Company
CHEMTREC:
Lilly Corporate Center
1-800-424-9300 (North America)
Indianapolis, IN 46285
1-703-527-3887 (International)
Common Name: Cefamandole Nafate for Injection
Chemical Name: 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-(formyloxy)
phenylacetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, monosodium salt, (6R,7R)-
Synonym(s): Vial Mandol 250 mg; Cefamandole; Cefamandole Nafate; Cefamandole Nafate Buffered;
Buffered Cefamandole Nafate; 106223 Formulation
Trademarks(s): Kefandol; Kefdole; Mandol; Mandol Injection; Mandokef; Kefadol
Lilly Item Code(s): AM7060; AM7061; AM7062; AM7064; AM7066; AM7067; AM7148; AM7169;
FS7208; FS7209; ND0677; ND0678; ND0679; ND0680; QA200A; QA297C; QA368Z; QA370Y;
QA382M; QA387U; QA440D; QI0185; QI0251; UC8962; VF0058; VF0064; VF0065; VF0066;
VF0196; VF0197; VL7059; VL7060; VL7061; VL7062; VL7063; VL7064; VL7066; VL7067;
VL7068; VL7069; VL7070; VL7071; VL7072; VL7074; VL7075; VL7076; VL7077; VL7119;
VL7120; VL7121; VL7122; VL7130; VL7131; VL7134; VL7138; VL7139; VL7169; VL7170;
VL7171; VL7172; VL7173; VL7174; VL7208; VL7209; VL7268; VL7269
See attached glossary for abbreviations.
Section 2 - Composition / Information on Ingredients
Ingredient CAS Concentration %
Cefamandole Nafate 42540-40-9 93.6
Sodium Carbonate Monohydrate 5968-11-6 6.3
Contains no hazardous components (one percent or greater) or carcinogens (one-tenth percent or
greater) not listed above.
Exposure Guidelines: Cefamandole nafate - LEG <100 micrograms/m3 TWA for 12 hours.
Sodium carbonate anhydrous - Exposure Guideline 500 micrograms/m3 TWA for 12 hours. (Lilly-
established guideline)
file://Z:\Legacy\EXTRACT 30NOV2006\MSDS_html\4273339.html 12/7/2006
Cefamandole Nafate for Injection Page 2 of 7
Section 3 - Hazards Identification
Appearance: White to off-white powder
Physical State: Solid
Odor: Odorless
Emergency Overview
Special
A = Allergen
Emergency Overview Effective Date: 02-Oct-1993
Lilly Laboratory Labeling Codes:
Health 1 Fire 1 Reactivity 1 Special A
Primary Physical and Health Hazards: Severe Allergen.
Caution Statement: Cefamandole Nafate for Injection causes severe allergic reactions.
Routes of Entry: Inhalation and skin contact.
Effects of Overexposure: Based on prior experience with cephalosporin antibiotics, allergic reactions
might be expected, including rash, nasal congestion, cough, dry throat, eye irritation, or anaphylactic
shock.
Medical Conditions Aggravated by Exposure: Hypersensitivity to penicillin or cephalosporin.
Carcinogenicity: All ingredients - No carcinogenicity data found. Not listed by IARC, NTP, ACGIH,
or OSHA.
Section 4 - First Aid Measures
Eyes: Flush eyes with plenty of water. Get medical attention.
Skin: Remove contaminated clothing and clean before reuse. Wash all exposed areas of skin with
plenty of soap and water. Get medical attention if irritation develops.
Inhalation: Move individual to fresh air. Get medical attention if breathing difficulty occurs. If not
breathing, provide artificial respiration assistance (mouth-to-mouth) and call a physician immediately.
Ingestion: Do not induce vomiting. Call a physician or poison control center. If available, administer
activated charcoal (6-8 heaping teaspoons) with two to three glasses of water. Do not give anything by
file://Z:\Legacy\EXTRACT 30NOV2006\MSDS_html\4273339.html 12/7/2006
Cefamandole Nafate for Injection Page 3 of 7
mouth to an unconscious person. Immediately transport to a medical care facility and see a physician.
Section 5 - Fire Fighting Measures
Flash Point: No applicable information found
UEL: No applicable information found
LEL: No applicable information found
Extinguishing Media: Use water, carbon dioxide, dry chemical, foam, or Halon.
Unusual Fire and Explosion Hazards: As a finely divided material, may form dust mixtures in air
which could explode if subjected to an ignition source.
Hazardous Combustion Products: May emit toxic fumes when exposed to heat or fire.
Section 6 - Accidental Release Measures
Spills: Wear protective equipment, including eye protection, to avoid exposure (see Section 8 for
specific handling precautions). Vacuum material with appropriate dust collection filter in place. Be
aware of potential for dust explosion when using electrical equipment. If vacuum is not available,
lightly mist material and remove by sweeping or wet wiping.
Section 7 - Handling and Storage
Storage Conditions: Controlled Room Temperature: 15 to 30 C (59 to 86 F).
Section 8 - Exposure Controls / Personal Protection
See Section 2 for Exposure Guideline information. Under normal use and handling conditions, no
protective equipment is required. The following is recommended for a production setting:
Respiratory Protection: Use an approved respirator.
Eye Protection: Chemical goggles and/or face shield.
Ventilation: Laboratory fume hood or local exhaust ventilation.
Other Protective Equipment: Chemical-resistant gloves and body covering to minimize skin
contact. If handled in a ventilated enclosure, as in a laboratory setting, respirator and goggles or face
shield may not be required. Safety glasses are always required.
Additional Exposure Precautions: In production settings, airline-supplied, hood-type respirators are
preferred. Shower and change clothing if skin contact occurs.
file://Z:\Legacy\EXTRACT 30NOV2006\MSDS_html\4273339.html 12/7/2006
Cefamandole Nafate for Injection Page 4 of 7
Section 9 - Physical and Chemical Properties
Appearance: White to off-white powder
Odor: Odorless
Boiling Point: No applicable information found
Melting Point: No applicable information found
Specific Gravity: No applicable information found
pH: 6.0-8.5 (10% solution)
Evaporation Rate: No applicable information found
Water Solubility: Soluble
Vapor Density: No applicable information found
Vapor Pressure: No applicable information found
Section 10 - Stability and Reactivity
Stability: Stable at normal temperatures and pressures.
Incompatibility: May react with strong oxidizing agents (e.g., peroxides, permanganates, nitric acid,
etc.).
Hazardous Decomposition: May emit toxic fumes when heated to decomposition.
Hazardous Polymerization: Will not occur.
Section 11 - Toxicological Information
Acute Exposure
Data for the active ingredient, cefamandole nafate, are presented.
Oral: Cefamandole nafate - Rat, 500 mg/kg, no deaths, reduced activity.
Skin: Cefamandole nafate - Rabbit, 500 mg/kg, no deaths or toxicity.
Inhalation: Cefamandole nafate - 2668 mg/m3 for 1 hour, no deaths or toxicity.
Intravenous: Cefamandole nafate - Rat, median lethal dose 2242 mg/kg, convulsions, incoordination,
labored breathing.
Dog, 1000 mg/kg, no deaths, vomiting.
Skin Contact: Cefamandole nafate - Rabbit, nonirritant
Eye Contact: Cefamandole nafate - Rabbit, slight irritant
Chronic Exposure
Data for the active ingredient, cefamandole nafate, are presented.
file://Z:\Legacy\EXTRACT 30NOV2006\MSDS_html\4273339.html 12/7/2006
Cefamandole Nafate for Injection Page 5 of 7
Target Organ Effects: Cefamandole nafate - No effects identified in animal studies.
Reproduction: Cefamandole nafate - No reproductive or developmental effects when administered to
mature animals. When administered to juvenile animals, testicular toxicity was observed.
Sensitization: Cefamandole nafate - Guinea pig, not a contact sensitizer.
Mutagenicity: No applicable information found.
Section 12 - Ecological Information
Environmental Summary:
Sodium carbonate anhydrous - Material is practically non-toxic to aquatic organisms. Material is
soluble in water and is expected to leach from soil into groundwater.
Section 13 - Disposal Considerations
Waste Disposal: Dispose of any cleanup materials and waste residue according to all applicable laws
and regulations.
Section 14 - Transport Information
Regulatory Organizations:
DOT: Not Regulated
ICAO/IATA: Not Regulated
IMO: Not Regulated
Section 15 - Regulatory Information
Below is selected regulatory information chosen primarily for possible Eli Lilly and Company
usage. This section is not a complete analysis or reference to all applicable regulatory
information. Please consider all applicable laws and regulations for your country/state.
U.S. Regulations
Cefamandole nafate
TSCA - No
CERCLA - Not on this list
SARA 302 - Not on this list
SARA 313 - Not on this list
OSHA Substance Specific - No
Remaining Ingredients
file://Z:\Legacy\EXTRACT 30NOV2006\MSDS_html\4273339.html 12/7/2006
Cefamandole Nafate for Injection Page 6 of 7
TSCA - Yes
CERCLA - Not on this list
SARA 302 - Not on this list
SARA 313 - Not on this list
OSHA Substance Specific - No
EU Regulations
EC Classification
Contains cefamandole nafate (C = 93.6%)
Xn (Harmful)
Risk Phrases
R 42/43 - May cause sensitization by inhalation and skin contact.
Safety Phrases
S 36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.
Section 16 - Other Information
MSDS Sections Revised: Section 16.
As of the date of issuance, we are providing available information relevant to the handling of this
material in the workplace. All information contained herein is offered with the good faith belief that it
is accurate. THIS MATERIAL SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE
ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this
material, this safety data sheet is not intended to be a substitute for consultation with appropriately
trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which
may accompany the finished product.
For additional information contact:
Eli Lilly and Company
Hazard Communication
317-651-9533
For additional copies contact:
Eli Lilly and Company
1-800-LILLY-Rx (1-800-545-5979)
GLOSSARY:
ACGIH = American Conference of Governmental Industrial Hygienists
AIHA = American Industrial Hygiene Association
BEI = Biological Exposure Index
CAS Number = Chemical Abstract Service Registry Number
CERCLA = Comprehensive Environmental Response Compensation and Liability Act (of 1980)
CHAN = Chemical Hazard Alert Notice
CHEMTREC = Chemical Transportation Emergency Center
file://Z:\Legacy\EXTRACT 30NOV2006\MSDS_html\4273339.html 12/7/2006
Cefamandole Nafate for Injection Page 7 of 7
DOT = Department of Transportation
EC = European Community
EINECS = European Inventory of Existing Chemical Substances
ELINCS = European List of New Chemical Substances
EPA = Environmental Protection Agency
HEPA = High Efficiency Particulate Air (Filter)
IARC = International Agency for Research on Cancer
ICAO/IATA = International Civil Aviation Organization/International Air Transport Association
IEG = Lilly Interim Exposure Guideline
IMO = International Maritime Organization
Kow = Octanol/Water Partition Coefficient
LEG = Lilly Exposure Guideline
LEL = Lower Explosive Limit
MSDS = Material Safety Data Sheet
MSHA = Mine Safety and Health Administration
NA = Not Applicable, except in Section 14 where NA = North America
NADA = New Animal Drug Application
NAIF = No Applicable Information Found
NCI = National Cancer Institute
NIOSH = National Institute for Occupational Safety and Health
NOS = Not Otherwise Specified
NTP = National Toxicology Program
OSHA = Occupational Safety and Health Administration
PEL = Permissible Exposure Limit (OSHA)
RCRA = Resource Conservation and Recovery Act
RQ = Reportable Quantity
RTECS = Registry of Toxic Effects of Chemical Substances
SARA = Superfund Amendments and Reauthorization Act
STEG = Lilly Short Term Exposure Guideline
STEL = Short Term Exposure Limit
TLV = Threshold Limit Value (ACGIH)
TPQ = Threshold Planning Quantity
TSCA = Toxic Substances Control Act
TWA = Time Weighted Average/8 Hours Unless Otherwise Noted
UEL = Upper Explosive Limit
UN = United Nations
WEEL = Workplace Environmental Exposure Level (AIHA)
file://Z:\Legacy\EXTRACT 30NOV2006\MSDS_html\4273339.html 12/7/2006
|